{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T23:20:09Z","timestamp":1772493609512,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,10]]},"DOI":"10.7759\/cureus.16307","type":"journal-article","created":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T04:27:16Z","timestamp":1625977636000},"source":"Crossref","is-referenced-by-count":3,"title":["Relapsed\/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?"],"prefix":"10.7759","author":[{"given":"Bushra","family":"Kanwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207843","article-title":"The epidemiology of non-Hodgkin's lymphoma","volume":"23","author":"Fisher SG","year":"2004","unstructured":"Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene. 2004, 23:6524-34. 10.1038\/sj.onc.1207843","journal-title":"Oncogene"},{"key":"ref2","unstructured":"NCI. Cancer stat facts. non-Hodgkin lymphoma. (2018). Accessed: April 12, 2021: https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2019.1680288","article-title":"Cost burden of diffuse large B-cell lymphoma","volume":"19","author":"Harkins RA","year":"2019","unstructured":"Harkins RA, Patel SP, Flowers CR. Cost burden of diffuse large B-cell lymphoma. Expert Rev Pharmacoecon Outcomes Res. 2019, 19:645-61. 10.1080\/14737167.2019.1680288","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos M","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011, 3:95ra73. 10.1126\/scitranslmed.3002842","journal-title":"Sci Transl Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00849","article-title":"CAR T-cell therapy for B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences","volume":"10","author":"Vitale C","year":"2020","unstructured":"Vitale C, Strati P. CAR T-cell therapy for B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences. Front Oncol. 2020, 10:849. 10.3389\/fonc.2020.00849","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross G","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989, 86:10024-8. 10.1073\/pnas.86.24.10024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2015.11.004","article-title":"Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors","volume":"37","author":"Harris DT","year":"2016","unstructured":"Harris DT, Kranz DM. Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors. Trends Pharmacol Sci. 2016, 37:220-30. 10.1016\/j.tips.2015.11.004","journal-title":"Trends Pharmacol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann J","year":"2017","unstructured":"Hartmann J, Sch\u00fc\u00dfler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017, 9:1183-97. 10.15252\/emmm.201607485","journal-title":"EMBO Mol Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo B","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E, et al.. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011, 121:1822-6. 10.1172\/JCI46110","journal-title":"J Clin Invest"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0421","article-title":"Chimeric antigen receptor T-cell therapy for the community oncologist","volume":"21","author":"Maus MV","year":"2016","unstructured":"Maus MV, Levine BL. Chimeric antigen receptor T-cell therapy for the community oncologist. Oncologist. 2016, 21:608-17. 10.1634\/theoncologist.2015-0421","journal-title":"Oncologist"},{"key":"ref11","unstructured":"FDA. KYMRIAH (tisagenlecleucel). (2019). Accessed. March 30, 2021: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah-tisagenlecleucel."},{"key":"ref12","article-title":"Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"130","author":"Schuster SJ","year":"2017","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al.. Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood. 2017, 130:577.","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2437_6","article-title":"Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)-an interim analysis","volume":"35","author":"Schuster S","year":"2017","unstructured":"Schuster S, Bishop MR, Tam C, et al.. Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)-an interim analysis. Hematol Oncol. 2017, 35:27. 10.1002\/hon.2437_6","journal-title":"Hematol Oncol"},{"key":"ref14","unstructured":"FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma. (2018). Accessed. April 12, 2021.: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-adults-relapsed-or-refra...."},{"key":"ref15","unstructured":"FDA. YESCARTA (axicabtagene ciloleucel). (2017). Accessed. 2021: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta-axicabtagene-ciloleucel."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke FL","year":"2017","unstructured":"Locke FL, Neelapu SS, Bartlett NL, et al.. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017, 25:285-95. 10.1016\/j.ymthe.2016.10.020","journal-title":"Mol Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu SS","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al.. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017, 377:2531-44. 10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136834","article-title":"Primary analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL)","volume":"27","author":"Jacobson C","year":"2021","unstructured":"Jacobson C, Chavez J, Sehgal A, et al.. Primary analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL). Blood. 2021, 27:67-8. 10.1182\/blood-2020-136834","journal-title":"Blood"},{"key":"ref19","unstructured":"FDA. FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma. (2020). Accessed. 2021: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-brexucabtagene-autoleucel-relapsed-or-ref...."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-179739","article-title":"How I treat mantle cell lymphoma","volume":"114","author":"Ghielmini M","year":"2009","unstructured":"Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood. 2009, 114:1469-76. 10.1182\/blood-2009-02-179739","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang M","year":"2020","unstructured":"Wang M, Munoz J, Goy A, et al.. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020, 382:1331-42. 10.1056\/NEJMoa1914347","journal-title":"N Engl J Med"},{"key":"ref22","unstructured":"FDA. FDA approves lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma. (2021). Accessed. 2021: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-l...."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.581.581","article-title":"High durable CR rates in relapsed\/refractory (R\/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND): NHL 001): defined composition allows for dose-finding and definition of pivotal cohort","volume":"130","author":"Abramson JS","year":"2017","unstructured":"Abramson JS, Palomba ML, Gordon LI, et al.. High durable CR rates in relapsed\/refractory (R\/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND): NHL 001): defined composition allows for dose-finding and definition of pivotal cohort. Blood. 2017, 130:581. 10.1182\/blood.V130.Suppl_1.581.581","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/62780-relapsedrefractory-non-hodgkin-lymphoma-engineering-t-cells-to-express-chimeric-antigen-receptors-cars-a-salvage","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:26:44Z","timestamp":1707506804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/62780-relapsedrefractory-non-hodgkin-lymphoma-engineering-t-cells-to-express-chimeric-antigen-receptors-cars-a-salvage"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,10]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.16307","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,10]]}}}